3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Metastatic Neuroendocrine Prostate Cancer
1
Advanced Solid Tumors
1
Interventions
Injections
8
pembrolizumab
4
Pemetrexed
4
Carboplatin
4
Oxaliplatin
3
Leucovorin
3
Fluorouracil
3
trifluridine tipiracil drug combination
2
sotorasib
2
fludarabine
2
Paclitaxel
2
Drug Therapy
2
Docetaxel
2
Bevacizumab
2
zimberelimab
1
trametinib
1
toripalimab
1
tislelizumab
1
sacituzumab govitecan
1
netrin-1 inhibitor NP137
1
cemiplimab
1
WW Domain-Containing Oxidoreductase
1
SYS6006 COVID-19 vaccine
1
Panitumumab
1
Irinotecan
1
Immune Checkpoint Inhibitors
1
Etoposide
1
Cyclophosphamide
1
Cisplatin
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Solid Tumors
×
Antiemetics
×
90 days
×
Clear all
NCT06242691
2026-06-05
MK-1200-002
Merck Sharp & Dohme LLC
Phase 1/2
Completed
13 enrolled
21 charts